OxStem, the University of Oxford’s regenerative drug discovery spin-off, has hired Georg Terstappen as chief scientific officer (CSO). Terstappen joins OxStem from GlaxoSmithKline’s research and development centre in Shanghai, where he served as head of platform technologies and science with responsibility for preclinical drug development. “Georg is a highly experienced scientist who brings an international perspective to our work on developing new medicines that target specific diseases or conditions,” said Professor David Sinclair, Head of Research at OxStem.
OxStem, the University of Oxford’s regenerative drug discovery spin-off, has hired Georg Terstappen as chief scientific officer (CSO). Terstappen joins OxStem from GlaxoSmithKline’s research and development centre in Shanghai, where he served as head of platform technologies and science with responsibility for preclinical drug development. As OxStem CSO, he will head up development work across the company’s portfolio of six programmes, which focus on stimulating progenitor and stem cell repair mechanisms within the body.